New paradigms in acute viral bronchiolitis: Is it time to change our approach?

Area of Science:

• Pediatric Respiratory Medicine
• Infectious Diseases
• Immunology

Background:

• Viral bronchiolitis is a leading cause of pediatric hospitalization globally.
• Current management primarily relies on supportive care due to limited efficacy of specific therapies.
• Emerging evidence suggests bronchiolitis is heterogeneous, with distinct phenotypes and endotypes.

Purpose of the Study:

• To review current evidence on bronchiolitis heterogeneity.
• To explore differences in pathobiology and clinical presentation based on viral etiology (e.g., RSV, rhinovirus).
• To assess the potential for individualized treatment strategies.

Main Methods:

• Comprehensive literature review of recent studies and clinical trials.
• Analysis of data on patient characteristics, etiology, and pathophysiological mechanisms.
• Evaluation of treatment responses in different patient subgroups.

Main Results:

• Bronchiolitis exhibits diverse forms with varying short- and long-term respiratory health outcomes, including asthma risk.
• Distinct pathobiology and immune responses are observed between respiratory syncytial virus (RSV) and rhinovirus infections.
• Certain subgroups of children may respond positively to systemic corticosteroids and/or bronchodilators.

Conclusions:

• Viral bronchiolitis is not a uniform condition but comprises multiple distinct entities.
• Individualized therapeutic approaches may be more effective than universal supportive management.
• Further research into endotypes and phenotypes can guide personalized treatment for better respiratory health outcomes.